Mizuho analyst Irina Koffler lowered her Botox Cosmetic and CoolSculpt estimates after conducting a survey of 20 dermatologists and plastic surgeons, who gave the impression that that the Botox franchise will be pressured by Evolus (EOLS) and other new entrants. Koffler cut her price target on Allergan shares to $171 from $194 based on the lowered estimates, but maintains a Buy rating on the stock, stating that it is "widely expected" that the company will make a strategic announcement that begins the preliminary work of separating the company in the next 1-2 months.